$700m · Series C · Healthtech · Stockholm, Sweden
Neko Health has raised a $700m Series C led by Lightspeed Venture Partners and co-led by O.G. Venture Partners. Existing investors Atomico, General Catalyst and Lakestar participated alongside Liberty City Ventures, Positive Sum and BDT & MSD. The company announcement says the funding will support its first US clinics, further geographic expansion and continued investment in preventive-health technology and research.
A clinic built around one repeatable scan
Neko sells a 60-minute, non-invasive health assessment that combines proprietary sensors with blood analysis and an in-person doctor consultation. The scan covers areas including skin, cardiovascular and metabolic risk, with results discussed during the same visit. In the UK it costs £299; the Swedish price is SEK 2,750.
The company builds the hardware, software and member experience in-house. Its latest update adds body-composition measurement and clinician review of wearable data, while new devices are being rolled out across its clinics. That vertical integration lets Neko change the scan and the operating workflow together, rather than waiting for several equipment and software suppliers to coordinate.
Repeat visits are the commercial test
Neko says more than 350,000 people have registered or joined its waitlist and more than 100,000 members in Sweden and the UK have completed a scan. It also reports that 75% book and prepay for the following year's appointment before leaving. Those are company-reported figures, but they identify the mechanism behind the model: a clinic earns more from its installed equipment and staff when members return regularly, while longitudinal data can make each later consultation more useful.
The Series C funds a much larger deployment challenge. Opening clinics requires property, regulated clinical operations, trained staff and new hardware, not just software distribution. Expansion into the US also introduces state-by-state operating requirements and a market where preventive scans have faced questions about cost, follow-up and whether broad screening improves outcomes for people without symptoms.
Neko's own data says three in four returning members with previously identified severe or life-threatening conditions were in good health or had the condition under control at their next scan. That is not the same as a controlled clinical trial, and the company will need broader evidence as it scales. The financing gives Neko unusual capacity to test whether its tightly integrated clinic model can reproduce demand, quality and repeat usage across new cities without losing the simplicity that attracts customers.
